Back to Results

Detection of resistance mechanisms in cerebrospinal fluid for EGFR-mutant, ALK- and ROS1-rearranged non-small cell lung cancer patients with central nervous system (CNS) progression after evidence of prior CNS benefit on relevant tyrosine kinase inhibitors

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Diagnostic

Locations

Georgetown University
University of Colorado Hospital
USC (Norris Hospital)

Principal Investigator
Ross Camidge,  MD, PhD

Ross Camidge, MD, PhD

Study ID

Protocol Number: 20-1193

More information available at ClinicalTrials.gov: NCT05116618

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers